The global cough suppressant market is estimated to be valued at USD 28,898.8 million in 2025 and is projected to reach USD 54,260.1 million by 2035, registering a compound annual growth rate of 6.5% over the forecast period.

Metrics	Value
Cough Suppressant Market Value 2025	USD 28,898.8 million
Projected Market Value 2035	USD 54,260.1 million
Value-based CAGR (2025 to 2035)	6.5%

Region Wise Analysis

Year	2025
Market Size (USD Billion)	28.6
CAGR (2025 to 2035)	6.4%

Year	2035
Market Size (USD Billion)	48.2
CAGR (2025 to 2035)	6.4%

Year	2025
Market Size (USD Billion)	4.64
CAGR (2025 to 2035)	3.1%

Year	2035
Market Size (USD Billion)	6.30
CAGR (2025 to 2035)	3.1%

Year	2025
Market Size (USD Billion)	8.77
CAGR (2025 to 2035)	6.9%

Year	2035
Market Size (USD Billion)	17.08
CAGR (2025 to 2035)	6.9%

Year	2025
Market Size (USD Billion)	6.01
CAGR (2025 to 2035)	7.3%

Year	2035
Market Size (USD Billion)	12.16
CAGR (2025 to 2035)	7.3%

Year	2025
Market Size (USD Billion)	3.2
CAGR (2025 to 2035)	6.1%

Year	2025
Market Size (USD Billion)	5.79
CAGR (2025 to 2035)	6.1%

According to Cognitive Market Research, the global cough medicine market size is USD 1658.2 million in 2024 and will expand at a compound annual growth rate (CAGR) of 6.00% from 2024 to 2031.

North America held the major market of more than 40% of the global revenue with a market size of USD 663.28 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.2% from 2024 to 2031.
Europe accounted for a share of over 30% of the global market size of USD 497.46 million.
Asia Pacific held the market of around 23% of the global revenue with a market size of USD 381.39 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.0% from 2024 to 2031.
Latin America holds the market of more than 5% of the global revenue with a market size of USD 82.91 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.
Middle East and Africa held the market of around 2% of the global revenue with a market size of USD 33.16 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031.
The Antihistamines held the highest cough medicine market revenue share in 2024.

Market Dynamics of Cough medicine Market

Key Drivers for Cough medicine Market

Rising prevalence of respiratory ailments to Increase the Demand Globally

The global upward push in respiration ailments, which include colds, flu, hypersensitive reactions, and persistent conditions, has brought about a widespread increase in cough-related symptoms. As the world's populace grows over a while, more people are becoming prone to respiratory ailments, contributing to a better prevalence of coughs. Additionally, urbanization and environmental elements, which include pollutants, can exacerbate respiration troubles. This trend drives a growing demand for cough suppressants and expectorants, with clients searching for alleviation from continual coughs. The pharmaceutical enterprise is responding by developing advertising and marketing a much wider variety of products to satisfy the needs of numerous populations, mainly as respiratory fitness turns into a growing concern in public fitness agendas globally.

Increasing geriatric population to Propel Market Growth

The international geriatric population is expanding, leading to a greater variety of elderly people who are at an extended chance for respiration infections and persistent coughs. As immune systems weaken with age, older adults are extra at risk of conditions like colds, flu, and pneumonia, resulting in a higher incidence of cough-related signs. This demographic shift contributes to a growing call for cough remedies, as the elderly are trying to find powerful solutions to manipulate their respiration fitness. Pharmaceutical groups are responding by creating merchandise tailor-made to the needs of older adults, focusing on protection and efficacy. As the older population continues to develop, the market for cough suppressants and expectorants is expected to expand, hence reflecting the unique fitness-demanding situations faced by means of seniors.

Restraint Factor for the Cough medicine Market

Stringent regulatory protocols to Limit the Sales

Stringent regulatory protocols are reshaping the production and distribution of cough syrups, particularly those containing codeine or different managed substances. Regulatory bodies across the globe are imposing stricter pointers to ensure the protection and accountable use of those medications in response to developing concerns about misuse and addiction. These rules can complicate the production system, requiring additional protection measures, compliance tests, and clean labeling. As a result, manufacturers face extended expenses and longer timelines to bring new cough drugs to market. This can create barriers to entry for smaller agencies and cause higher prices for consumers. Despite these demanding situations, stringent protocols are important for public protection, aiming to lessen the dangers related to amazing cough suppressant.

Impact of Covid-19 on the Cough medicine Market

The COVID-19 pandemic had a profound effect on the cough medication marketplace. As respiratory signs, which include cough, have become intently associated with COVID-19, the call for cough medicines surged. Initially, this caused delivery chain disruptions and inventory shortages as consumers rushed to pharmacies to stockpile over-the-counter remedies. Ma...

The Cough Remedies Market Report is Segmented by Product Type (Antitussives, Expectorants, and More), Dosage Form (Syrup/Linctus, Tablets & Capsules, and More), Age Group (Pediatrics & Adolescents (Below 18 Years), and More), Distribution Channel (Retail Pharmacies, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

The over-the-counter (OTC) cough, cold, and allergy medicine market is a substantial and dynamic sector within the pharmaceutical industry. While precise figures for market size and CAGR are absent from the provided data, we can infer considerable growth potential based on the listed key players and the consistent demand for these products. The market is driven by factors such as rising prevalence of respiratory illnesses, increasing awareness of self-medication, and convenient accessibility through various retail channels. Emerging trends like the development of targeted formulations (e.g., for specific age groups or allergy types), the incorporation of natural ingredients, and the rise of digital health platforms for symptom tracking and advice are shaping the market landscape. However, regulatory scrutiny, potential side effects of some medications, and the availability of alternative therapies represent key restraining factors. Segmentation likely exists across product types (e.g., cough suppressants, decongestants, antihistamines), distribution channels (pharmacies, supermarkets, online retailers), and geographic regions. The presence of numerous multinational pharmaceutical companies like Sanofi-Aventis, Johnson & Johnson, and Pfizer, alongside significant players in the Asian market (e.g., Sinopharm Group, CSPC), indicates a competitive yet established market structure. Future growth will hinge on innovation, effective marketing strategies, and successful navigation of the evolving regulatory landscape. The market's growth trajectory is likely influenced by seasonal variations in respiratory illness incidence. Higher sales are typically observed during cold and flu seasons, leading to fluctuations in the annual growth rate. Given the established market and the presence of major pharmaceutical companies, a conservative estimate of the overall market size would be in the billions of dollars, with a moderate CAGR in the low single digits, reflecting both steady growth and periods of market saturation. Companies are likely focused on enhancing their product portfolios with innovative formulations, improving marketing efforts to increase brand loyalty, and expanding their presence in emerging markets. The strategic mergers and acquisitions observed in the pharmaceutical industry further contribute to this market's evolution and consolidation. This necessitates a thorough understanding of consumer behavior and health trends for success within this competitive landscape.

Find detailed analysis in Market Research Intellect's Children Cough Medicine Market Report, estimated at USD 3.5 billion in 2024 and forecasted to climb to USD 5.2 billion by 2033, reflecting a CAGR of 5.7%.Stay informed about adoption trends, evolving technologies, and key market participants.

Learn more about the Cough Medicine Market Report by Market Research Intellect, which stood at USD 4.5 billion in 2024 and is forecast to expand to USD 6.8 billion by 2033, growing at a CAGR of 5.5%.Discover how new strategies, rising investments, and top players are shaping the future.

The sales value of over-the-counter (OTC) cough, cold and sore throat treatments in Great Britain stood at over *** million British pounds in 2024. This was the highest value in the provided time interval. OTC medicine market in Great Britain  Cough, cold and sore throat medication had the second-highest sales value in 2024, when broken down by OTC drug categories. Pain relief medication was the category with the highest sales value, at approximately *** million British pounds. Vitamins and minerals had a sales value of *** million British pounds, the third-highest category overall in Great Britain. Overall, the sales value of OTC drugs has increased from **** billion British pounds in the year 2000 to over four billion British pounds in 2024.  Growth of other OTC categories The OTC product category which had the highest growth of sales value in Great Britain from 2023 and 2024 was cough and cold, with a significant growth of **** percent. This was followed by vitamins and minerals, which grew by ***** percent compared to the previous year. 

The global cough syrup market size reached USD 6.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 8.5 Billion by 2033, exhibiting a growth rate (CAGR) of 3.65% during 2025-2033. The increasing occurrence of upper respiratory tract infections (URTIs) and other respiratory disorders, along with the easy availability of cough syrups in general stores and pharmacies, is primarily driving the market growth.

Report Attribute	Key Statistics
Base Year	2024
Forecast Years	2025-2033
Historical Years	2019-2024
Market Size in 2024	USD 6.1 Billion
Market Forecast in 2033	USD 8.5 Billion
Market Growth Rate (2025-2033)	3.65%

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2025-2033. Our report has categorized the market based on the product type, age group and distribution channel.

The global cough and cold medicine market is a substantial sector experiencing steady growth. While precise figures for market size and CAGR aren't provided, a reasonable estimation, considering the prevalence of respiratory illnesses and the established presence of major pharmaceutical players like Pfizer and Johnson & Johnson, suggests a market size exceeding $20 billion in 2025. Assuming a conservative Compound Annual Growth Rate (CAGR) of 5% based on industry trends and considering factors such as increasing prevalence of respiratory infections, aging populations, and the introduction of new formulations, the market is projected to reach approximately $26 billion by 2033. This growth is fueled by several key drivers, including rising healthcare expenditure, increasing awareness of self-medication, and the development of more effective and targeted treatments. Market segmentation is diverse, encompassing various formulations (liquid syrups, capsules, pills) and target demographics (adults and children). The significant presence of established pharmaceutical companies indicates a competitive landscape with considerable research and development investment in innovative products. However, market growth isn't without its restraints. Stringent regulatory approvals, the potential for adverse drug reactions, and the rise of alternative and homeopathic remedies pose challenges. Regional variations exist, with North America and Europe anticipated to hold substantial market shares due to higher healthcare spending and established pharmaceutical infrastructure. Emerging markets in Asia-Pacific, driven by population growth and increasing disposable incomes, are expected to exhibit significant growth potential in the coming years. The market will likely witness continuous innovation in formulation, focusing on targeted therapies, improved efficacy, and reduced side effects. This ongoing evolution necessitates constant market monitoring and adaptation by both established players and emerging competitors.

The global cough suppressant market is a significant sector within the pharmaceutical industry, exhibiting robust growth driven by factors such as increasing prevalence of respiratory illnesses, rising geriatric population (more susceptible to respiratory issues), and growing awareness of effective cough management. The market size in 2025 is estimated at $15 billion, reflecting a Compound Annual Growth Rate (CAGR) of 5% over the period 2019-2024. This growth trajectory is expected to continue, with a projected CAGR of 6% from 2025 to 2033, resulting in a market value exceeding $25 billion by 2033. Key market drivers include the development of novel, more effective formulations with reduced side effects, increased demand for over-the-counter (OTC) cough remedies, and expanding access to healthcare in emerging economies. Emerging trends include the rise of herbal and natural cough suppressants, increasing use of digital platforms for diagnosis and treatment information, and the focus on personalized medicine approaches to cough management. However, the market faces certain restraints such as stringent regulatory approvals for new drug launches, potential side effects associated with long-term use of some cough suppressants, and the rise of self-medication practices without proper medical consultation. The competitive landscape is dominated by major pharmaceutical players like Pfizer, Novartis, Merck, Johnson & Johnson, and smaller specialized companies like Atley and Vertical Pharmaceuticals. These companies are actively engaged in research and development to introduce innovative products, expand their market presence geographically, and strengthen their brand portfolios. Strategic collaborations, mergers, and acquisitions are also contributing to market consolidation. Regional market variations are expected, with North America and Europe holding significant market shares due to higher healthcare expenditure and better access to advanced medical treatments. However, Asia-Pacific is projected to witness substantial growth due to increasing population, rising disposable incomes, and growing awareness about respiratory health. This expanding market presents significant opportunities for both established and emerging players, prompting ongoing investment in research, product innovation, and strategic market expansion.

Rise in the prevalence of immunosuppressive conditions and growth of elderly population are projected to drive demand for OTC cold and cough medicine market during the forecast period.

Comparing the ** selected regions regarding the revenue in the 'Cold & Cough Remedies' segment of the otc pharmaceuticals market, the United States is leading the ranking (**** billion U.S. dollars) and is followed by China with *** billion U.S. dollars. At the other end of the spectrum is Saudi Arabia with ****** million U.S. dollars, indicating a difference of **** billion U.S. dollars to the United States. Find other insights concerning similar markets and segments, such as a ranking of subsegments in Europe regarding revenue in the OTC Pharmaceuticals market as a whole and a ranking by country regarding revenue in the OTC pharmaceuticals market. The Statista Market Insights cover a broad range of additional markets.

The over-the-counter (OTC) children's cough medicine market is a substantial sector, projected to reach $1389.6 million in 2025 and exhibiting a robust Compound Annual Growth Rate (CAGR) of 9.2% from 2025 to 2033. This growth is fueled by several key factors. Increasing prevalence of respiratory illnesses in children, coupled with rising parental awareness regarding convenient and effective self-treatment options, drives significant demand. Furthermore, the market benefits from continuous innovation in formulation and delivery systems, leading to products with improved palatability and efficacy for young patients. The rise in disposable incomes in developing economies also contributes to market expansion, as more parents opt for branded OTC medications. However, stringent regulatory guidelines regarding the safety and efficacy of pediatric medications and increasing concerns about the potential side effects of some cough suppressants present notable challenges to sustained growth. Competition among established players such as Johnson & Johnson, Reckitt Benckiser, and Sanofi, alongside emerging regional brands, further shapes the market landscape. The competitive landscape is characterized by a blend of global giants and regional players. Key players strategically focus on product diversification, expanding distribution networks, and engaging in targeted marketing campaigns to capture larger market shares. Market segmentation is likely driven by product type (cough suppressants, expectorants, combination therapies), age group (infants, toddlers, older children), and distribution channels (pharmacies, supermarkets, online retailers). Regional variations in healthcare infrastructure and consumer preferences influence market dynamics. Future growth will likely be influenced by advancements in pediatric respiratory medicine, evolving consumer preferences toward natural or herbal remedies, and the increasing adoption of telemedicine platforms for healthcare consultations. Continued regulatory scrutiny and a focus on product safety will remain paramount for market participants.

The North America Cough Medicine report provides a detailed analysis of emerging investment pockets, highlighting current and future market trends. It offers strategic insights into capital flows and market shifts, guiding investors toward growth opportunities in key industry segments and regions.

Over-the-counter (OTC) cough and cold medicines are central to supporting public health and alleviating the strain on the healthcare system, leading this industry to contribute billions annually to the economy. Between 2020 and 2025, OTC cough and cold manufacturers have seen this role expand, contributing to strong revenue growth. However, a mix of pandemic-driven surges, unpredictable seasonal illness patterns, evolving consumer behavior and cost pressures have weakened profit. After an unexpected decline in 2020 because of widespread masking and low virus transmission, the category rebounded in 2021 and 2022, with established players and private-label brands benefitting from elevated health awareness and increased household stock. However, this momentum proved difficult to sustain as demand cooled off because of a mild respiratory season and lingering inventory, resulting in softer sales volumes and weakening profit in 2023 and 2024. Manufacturers can expect stabilizing demand in 2025 but still face operating pressures from external and internal factors. In all, revenue has been rising at a CAGR of 12.7% to an estimated $12.0 billion, including expected growth of 2.1% in 2025. Cough and cold medicine manufacturers have also been contending with rising costs. Labor wages are at all-time highs, ingredient and packaging prices have remained volatile and increased regulatory scrutiny—especially from the FDA and FTC—is adding to compliance costs. At the same time, pricing power has weakened because of steep competition from leading manufacturers, like Reckitt and Kenvue, and store brands at retailers like Walmart and Costco, which continue to grow their share through lower prices and expanded shelf space. R&D investments have also been critical to meet the evolving demand for formulas with cleaner, natural ingredients. This environment makes the industry cost-conscious, with profit increasingly tied to operating efficiency and an adaptable supply chain. The industry faces a more complex environment moving forward. Demographic shifts—like an aging population and rising health engagement among younger consumers—support long-term stability. Still, manufacturers must navigate forecasting unpredictable illness patterns and demand surges tied to virus evolution or seasonality. Manufacturers investing in automation, localizing supply chains and developing differentiated, multi-functional products are best positioned to manage these pressures. While the industry’s role in the broader consumer health market will support growth, with revenue expanding at a CAGR of 2.7% to an estimated $13.8 billion over the next five years, manufacturers must be agile to strengthen profit.

The global market for cough and cold preparations is a substantial and consistently growing sector. While the exact market size for 2025 isn't provided, considering a CAGR of 5% and a typical market size in this sector, a reasonable estimation for the 2025 market value would be around $20 billion USD. This robust market is driven by several factors, including the increasing prevalence of respiratory illnesses globally, rising disposable incomes in emerging economies leading to increased healthcare spending, and the readily available over-the-counter (OTC) nature of many cough and cold remedies. Key trends shaping the market include the growing demand for herbal and natural remedies, the development of targeted formulations for specific age groups and symptoms (such as pediatric formulations), and a focus on convenient dosage forms like single-dose packets. However, factors such as stringent regulatory approvals for new drug launches, increasing generic competition impacting pricing, and growing consumer awareness of potential side effects of certain medications pose challenges to market growth. The market is highly competitive, with a mix of established pharmaceutical giants like GlaxoSmithKline, AstraZeneca, and Pfizer, alongside smaller, specialized companies and regional players. Companies are constantly innovating to improve product efficacy and safety, while marketing strategies heavily emphasize brand awareness and consumer education. The market is segmented by product type (e.g., cough suppressants, expectorants, decongestants, combination products), by distribution channel (e.g., pharmacies, online retailers, supermarkets), and geographically. Projected growth over the forecast period (2025-2033) at a 5% CAGR suggests a significant expansion in market value, indicating promising investment opportunities for existing players and new entrants alike. The increasing prevalence of chronic respiratory conditions and an aging global population are expected to continue fueling demand.

BASE YEAR	2024
HISTORICAL DATA	2019 - 2023
REGIONS COVERED	North America, Europe, APAC, South America, MEA
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
MARKET SIZE 2024	1,900(USD Million)
MARKET SIZE 2025	1,900(USD Million)
MARKET SIZE 2035	3,000(USD Million)
SEGMENTS COVERED	Product Type, Formulation, Distribution Channel, Target Age Group, Regional
COUNTRIES COVERED	US, Canada, Germany, UK, France, Russia, Italy, Spain, Rest of Europe, China, India, Japan, South Korea, Malaysia, Thailand, Indonesia, Rest of APAC, Brazil, Mexico, Argentina, Rest of South America, GCC, South Africa, Rest of MEA
KEY MARKET DYNAMICS	Rising prevalence of respiratory illnesses, Increasing demand for pediatric medications, Growing health awareness among parents, Innovation in cough medicine formulations, Expanding pharmaceutical distribution channels
MARKET FORECAST UNITS	USD Billion
KEY COMPANIES PROFILED	Bayer, Pfizer, Novartis, Reckitt Benckiser, Performance Health, Mylan, Hero MotoCorp, GlaxoSmithKline, Haleon, Sun Pharmaceutical Industries, Johnson & Johnson, AbbVie, Sanofi, Boehringer Ingelheim, AstraZeneca
MARKET FORECAST PERIOD	2025 - 2035
KEY MARKET OPPORTUNITIES	Natural ingredient formulations, Increased online sales channels, Growing awareness of childhood respiratory health, Rising demand for preventive health solutions, Expansion in emerging markets
COMPOUND ANNUAL GROWTH RATE (CAGR)	4.4% (2025 - 2035)

The over-the-counter (OTC) children's cough medicine market, valued at $1322 million in 2025, is projected to experience robust growth, exhibiting a compound annual growth rate (CAGR) of 8.8% from 2025 to 2033. This growth is fueled by several key drivers. Increasing prevalence of respiratory illnesses in children, coupled with rising parental awareness about the importance of early intervention and symptom management, is a significant factor. Furthermore, the market benefits from continuous innovation in formulation, leading to the development of more effective and palatable medications with reduced side effects. The introduction of herbal and homeopathic alternatives alongside traditional formulations also contributes to market expansion, catering to diverse consumer preferences. However, stringent regulatory approvals and safety concerns regarding certain ingredients pose challenges, potentially hindering growth. The market is segmented by product type (syrups, lozenges, etc.), age group, and distribution channel (pharmacies, online retailers, etc.), each segment presenting unique growth opportunities. Major players like Johnson & Johnson, Reckitt Benckiser, and Sanofi are actively engaged in research and development, strategic partnerships, and expanding their product portfolios to maintain market competitiveness. The geographic distribution likely varies, with developed nations contributing a larger share initially, followed by steady growth in emerging economies due to rising disposable incomes and healthcare awareness. The competitive landscape is characterized by a mix of established multinational corporations and regional players. The success of companies will depend on their ability to innovate, maintain high quality standards, and effectively target specific consumer segments through targeted marketing and appropriate distribution channels. Future market growth will likely be influenced by factors such as changes in healthcare policies, evolving consumer preferences, and the emergence of novel treatment options. The market is expected to show consistent growth in the forecast period, driven by the ongoing need for effective and safe cough and cold remedies for children. Continuous monitoring of consumer trends and regulatory landscape will be vital for companies seeking long-term success in this dynamic market.

The global cough remedies market, valued at approximately $XX million in 2025, is projected to experience robust growth, exhibiting a Compound Annual Growth Rate (CAGR) of 7.10% from 2025 to 2033. This expansion is driven by several key factors. Rising prevalence of respiratory infections, particularly in densely populated urban areas and regions with fluctuating climates, fuels demand for effective cough relief. Increased awareness of self-medication options and readily available over-the-counter (OTC) cough remedies contribute significantly to market growth. Furthermore, the continuous innovation in formulation and delivery methods, such as the development of extended-release formulations and targeted therapies, caters to evolving consumer preferences and enhances treatment efficacy. However, potential market restraints include the growing concerns regarding side effects associated with certain cough suppressants, the increasing preference for natural remedies and herbal formulations, and the stringent regulatory approvals required for new drug launches. The market segmentation reveals a diverse landscape, with oral syrups maintaining a dominant share in the dosage form category due to their ease of administration, especially for children and the elderly. Within product types, antihistamines and expectorants together comprise a substantial portion of the market, reflecting their wide-ranging applications in addressing various cough symptoms. Major players like AstraZeneca, Bayer, GlaxoSmithKline, and Johnson & Johnson are actively engaged in product innovation, strategic collaborations, and market expansion strategies to maintain their competitive edge in this dynamic market. Geographical distribution shows North America and Europe as mature markets, while Asia Pacific is emerging as a high-growth region, driven by increasing healthcare expenditure and rising disposable incomes. The market is characterized by intense competition among established pharmaceutical giants and emerging players. The forecast period will likely witness further consolidation through mergers and acquisitions, alongside a rise in the popularity of targeted drug delivery systems and personalized medicine approaches to cough relief. The growing use of telehealth and online pharmacies also presents significant opportunities for market expansion. The increasing focus on improving air quality and public health initiatives further support a positive outlook for the cough remedies market. However, ongoing challenges related to pricing pressures, generic competition, and fluctuating raw material costs require careful management by market players. Key drivers for this market are: , Growing Awareness About Cough Remedies; Increasing Demand for Over-the-Counter (OTC) Products; Integration of Advanced Medicines. Potential restraints include: , Growing Awareness About Cough Remedies; Increasing Demand for Over-the-Counter (OTC) Products; Integration of Advanced Medicines. Notable trends are: The Oral Syrup Dominates the Dosage Form Segment of the Market and is Expected to Continue the Same during the Forecast Period.

The revenue change in the 'Cold & Cough Remedies' segment of the otc pharmaceuticals market in the Philippines was modeled to amount to **** percent in 2024. Between 2017 and 2024, the revenue change rose by **** percentage points, though the increase followed an uneven trajectory rather than a consistent upward trend. The revenue change is forecast to decline by **** percentage points from 2024 to 2029, fluctuating as it trends downward.Further information about the methodology, more market segments, and metrics can be found on the dedicated Market Insights page on Cold & Cough Remedies.